Prognose
Analytikernes gennemsnitlige kursmål er 54,08 € (+89,42 %). Medianen er 55,60 € (+94,75 %).
| Køb |
14 |
| Behold |
0 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Pharvaris presents Deucrictibant ahead of market launch after strong phase‑III data
Pharvaris unveiled final plans for Deucrictibant at the Morgan Stanley Healthcare Conference. The oral HAE drug showed Phase‑III efficacy of 87% in HAE types 1 and 2 (83% in the extended population). The company is targeting U.S. approval for on‑demand treatment with a PDUFA target date of April 2027 and is preparing a prophylactic indication thereafter. Management highlighted a favorable safety profile versus competing oral therapies, plans to build a commercial organization (target: ~90 employees) and expects liquidity into mid‑2028 in the base case. Additional data from CREATE and an open‑label extension study are expected to be released in the coming months. » Mere på de.investing.com
Pharvaris shows phase‑III success: Deucrictibant reduces HAE attacks by 87%
At the Cantor Fitzgerald conference Pharvaris presented phase‑III data (CHAPTER‑3) showing an 87% reduction in hereditary angioedema attacks with the oral B2‑receptor antagonist Deucrictibant. The study included patients from six continents and used an extended‑release formulation that may explain the improved efficacy profile. Safety questions remain: two grade‑3 elevations in liver enzymes and one serious laryngeal event were reported, though the company considers the overall profile comparable to existing prophylactics. Pharvaris plans to launch the on‑demand treatment on April 8, 2025, and aims to file for approval for prophylaxis in the first half of 2025, supported by a targeted commercial platform for bradykinin‑mediated angioedemas. » Mere på de.investing.com
Pharvaris: oral HAE drug deucrictibant shows strong phase‑III data
Deucrictibant reduced HAE attacks by 87% in the phase‑III prophylaxis study in type‑1/ type‑2 patients (83% in the overall population) and replicated earlier results in a larger, global cohort. Pharvaris expects a PDUFA date for the on‑demand formulation on April 23 and plans to submit the regulatory application for the prophylaxis version in H1 2025. Two cases of elevated liver enzymes were reported but, according to management, are comparable to known risks; long‑term safety is being investigated in the open‑label extension study CHAPTER‑4. Commercially, the company intends to target treatment‑naive patients as well as users of ORLADEYO and injectable therapies. » Mere på de.investing.com
Pharvaris rises sharply after positive phase‑3 data for HAE drug
Pharvaris reported statistically significant topline results from the pivotal phase‑3 study CHAPTER‑3: Deucrictibant XR reduced the mean monthly HAE attack rate by 83% versus placebo (p<0.0001) and lowered the rate in HAE type 1/2 by 87%. All secondary endpoints were significant and the safety profile proved well tolerated. The company intends to use the data for regulatory submissions, including a New Drug Application in the US in the first half of 2027, and the stock then reached a new 52‑week high. » Mere på de.investing.com
Pharvaris: Phase‑3 study of Deucrictibant XR meets primary endpoint and markedly reduces HAE attacks
Pharvaris reports that the Phase‑3 CHAPTER‑3 study of Deucrictibant XR met its primary endpoint for prevention of hereditary angioedema (HAE) attacks. A once‑daily 40 mg dose reduced the mean monthly attack rate across all three HAE types by 83% versus placebo and by 87% in HAE types 1 and 2; all secondary endpoints were also statistically significant. Protection began in the first week of treatment and was maintained over 24 weeks. Deucrictibant XR was well tolerated, with no treatment‑related serious adverse events. Pharvaris plans to use the CHAPTER‑3 data to support regulatory filings and intends to submit a New Drug Application to the FDA in the first half of 2027. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalI 2022 har Pharvaris Aktie allerede udloddet 0,10 € i udbytte. Den seneste udlodning fandt sted i juli 2022.
Virksomhedstal
I det seneste kvartal havde Pharvaris Aktie en omsætning på 0 € og et nettoresultat på -47,41 mio. €
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 0 | - |
| Bruttofortjeneste | 0 | - |
| Nettoresultat | -47,41 mio. | 27,67 % |
| EBITDA | -49,99 mio. | 34,33 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 2,02 mia. € |
Antal aktier | 70,79 mio. |
Højeste/laveste i 52 uger | 39,42 € - 21,10 € |
| Udbytte | Nej |
Beta | -2,48 |
P/E (PE Ratio) | -10,29 |
PEG (PEG Ratio) | -2,45 |
K/I (PB Ratio) | 7,57 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
Pharvaris N.V., et klinisk-stadie biofarmaceutisk selskab, fokuserer på udvikling og kommercialisering af terapier til sjældne sygdomme. Selskabet udvikler PHA121, en småmolekylær bradykinin B2-receptorantagonist, som er i fase II-klinisk forsøg til behandling af hereditært angioødem (HAE). Det udvikler også PHVS416, en on-demand-blødkapsel med hurtig eksponering til patienter, der lider af akutte HAE-anfald, og som er i fase 2-klinisk forsøg; samt PHVS719, en profylaktisk tablet med forlænget frigivelse til HAE-patienter, og som er i fase 1-klinisk forsøg. Selskabet opererer i Holland, Schweiz og USA. Selskabet blev stiftet i 2015 og har hovedsæde i Leiden, Holland.
| Navn | Pharvaris Aktie |
| CEO | Berndt Modig |
| Hjemsted | Zug,
zh Nederlandene |
| Websted | |
| Sektor | Materialer |
| Branche | Kemikalier |
| Børsnotering | 05.02.2021 |
| Medarbejdere | 148 |
Deep Dive
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | PHVS |
Frankfurt | 9EN.F |
Düsseldorf | 9EN.DU |
München | 9EN.MU |